What we are researching
The purpose of this study is to look into how the study medicine works on the structure and function of the heart in people living with heart failure, with preserved ejection fraction, and left ventricular hypertrophy.
Who may participate
Each clinical trial has its own requirements for who can participate, often called eligibility criteria. Some of the key criteria for this study are listed here. Discuss these requirements with your study doctor to determine if you may be eligible to participate. Additional criteria for your doctor to review can be found here NCT06979362.
Heart Failure
Have been diagnosed with symptomatic heart failure, at least 90 days before joining the study, with at least a weekly need for oral diuretic treatment
Current Treatment
Be on stable treatment, with medicine for heart failure, at least 45 days before starting the study medicine
Age
40 to 84 years
Study Medicine
IV infusion every 4 weeks
Number of study visits
Main - About 14 visits over a period of about 7 months
Extension - About 13 visits over a period of about 8 months
What to expect
If your study doctor determines that you are eligible and you decide to participate, you will be enrolled into the study.
The study consists of two phases: a main phase and an extension. In the main phase, you will be randomly assigned to receive either the study medicine at one of three dose levels or placebo (which has no active medicine in it). If you continue in the extension, you will be randomly re-assigned to receive either your main phase treatment or placebo. All study treatment options are given as intravenous (IV) infusions.
The main phase will last about 7 months, with in-person visits every 1 to 3 weeks. If you continue into the extension, your participation will last another 8 months, with in-person visits every 1 to 3 weeks. Visits may include physical exams, lab tests and questionnaires to monitor your health and safety.
Call 866-867-7178 or email clinicaltrials@novonordisk.com to learn more
about the study and find out whether there is a participating study site near you.
When you call, please reference study 8212 or 8212-Preserved
You may also choose to discuss this clinical trial with your healthcare provider.